Adherence of Iron Succinylate Therapy in Pregnancy
Key facts
- Who runs it
- Elpen Pharmaceutical Co. Inc.
- Where
- Greece1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 30 Dec 2022
- Ended
- 30 Dec 2023
- Type of study
- Observational
- Record updated
- 15 February 2023
- Why it stopped
- Modification of clinical development plan
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Pregnancy
- Anaemia
- Iron treatment before 3 months of pregnancy
- Informed Consent
- Compliant with study procedures
Who cannot take part
- Iron treatment after 3 months of pregnancy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
According to the World Health Organization (WHO), anemia is the most common disease, affecting >1.5 billion people worldwide. Furthermore, iron deficiency anemia (IDA) accounts for 50% of cases of anemia. IDA is common during pregnancy and the postpartum period, and can lead to serious maternal and fetal complications. Measurement of serum ferritin has the highest sensitivity and specificity for diagnosis of IDA unless there is a concurrent inflammatory condition. The lower threshold value for hemoglobin (Hb) in pregnant women is <11 g/dL during the 1st and 3rd trimesters, and <10.5 g/dL during the 2nd trimester. In postpartum period a Hb concentration <10 g/dL indicates clinically significant anemia. Oral iron therapy is given as the first-line treatment for IDA.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Observational Study to Examine the Iron Treatment in Pregnant Women With Anaemia
- Record updated
- 15 February 2023